Oral therapy for rosacea

Journal of Drugs in Dermatology, Jan, 2006 by Hilary E. Baldwin

9. Thong Y, Ferrante A. Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues. Clin Exp Immunol. 1979;35:443-446.

10. Greenwald R, Moak S, Ramamurthy N, et al. Tetracycline suppresses matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. J Rheumatol. 1992;19:927-938.

11. Golub L, Ciancio S, Ramamurthy N, et al. Low-dose doxycycline therapy: effect on gingival crevicular fluid collagenase activity in humans. J Periodontal Res. 1990;25:321-330.

12. Alexander M, Damoulis P. The role of cytokines in the pathogenesis of periodontal disease. Curr Opin Periodontol. 1994;3:53.

13. Marks R. Concepts in the pathogenesis of rosacea. Br J Dermatol. 1968;80:170-177.

14. Golub L, Lee H, Ryan M, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.

15. Sneddon I. A clinical trail of tetracycline in rosacea. Br J Dermatol. 1966;78:649-652.

16. Dahl M, Katz H, Krueger G, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-683

17. Knight A, Vickers C. A follow-up of tetracycline-treated rosacea with special reference to rosacea keratitis. Br J Dermatol. 1975;93:577-580

18. Bikowski J. Subantimicrobial dose doxycycline for acne and rosacea. SKINmed. 2003;2:234-245.

19. Skidmore, R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459-464.

20. Thomas J, Walker C, Bradshaw M. Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Periodontol. 200;71:1472-1483.

21. Bikowski J. New approaches to rosacea therapy. Skin Aging. 2005:13(suppl 2):13-15.

22. Del Rosso J. Systemic therapy for rosacea: focus on oral antibiotic therapy and safety. Cutis. 2000;66:713.

23. Rebora A. The management of rosacea. Am J Clin Dermatol. 2002;3:489-496.

24. Bikowski J. Rosacea: a tiered approach to therapy. Cutis. 2000;66(supl 4):3-6.

25. Torresani C, Pavesi A, Manata G. Clarithromycin versus doxycycline in the treatment of rosacea. Int J Dermatol. 1997;36:942-946.

26. Torresani C. Clarithromycin: a new perspective in rosacea treatment. Int J Dermatol. 1998;37:347-349.

27. Bakar O, Demircay Z, Gurbuz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol. 2004;43:151.

28. Pelle M, Crawford G, James W. Rosacea: II. Therapy. J Am Acad. Dermatol. 2004;51:499-512.

29. Pye R, Burton J. Treatment of rosacea by metronidazole. Lancet. 1976;1:1211-1212.

30. Saihan E, Burton J. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Dermatol. 1980;102:443-445.

31. Guilhou J, Meynadier J, Guilhou E, et al. Treatment of rosacea with metronidazole. Nouv Presse Med. 1978;7:1960-1961.

32. Stieger M. Metronidazole (Flagyl) as a therapy variant in rosacea and in perioral dermatitis. Z Hautkr. 1979;54:671-672.

33. Saihan E, Burton J. A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea. Br J Clin Pharmacol. 1997;44:179-182.